Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inclisiran for coronary plaque progression in non-obstructive coronary artery disease
CTR20221867Phase 3Completed
- Sponsor
- Novartis
- Start
- Feb 2023
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of inclisiran in coronary arteriosclerosis, atherosclerosis, sponsored by Novartis. Started Feb 2023; status: completed.
02
Drugs
inclisiran
03
Conditions
coronary arteriosclerosisatherosclerosis
Beyond the preview
Go deeper on CTR20221867.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20221867.